← ANALYST RATINGS · TIPRANKS
X4 Pharmaceuticals (XFOR): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $11.00, the highest $12.00, the lowest $10.00. The average is +324.7% from the last price of $2.59.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $2.50−16.7% | Hold | −3.5% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Hold | −3.5% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Hold | −3.5% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $2.50−16.7% | Hold | −3.5% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Sell | −3.5% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $2.50−16.7% | Hold | −3.5% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $11.00 | Buy | +324.7% | Reiterated | 09.09.26on TipRanks 07:35 | +3.2%next day −5.0% · 5 days −1.4% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $12.00 | Buy | +363.3% | Reiterated | 08.09.26on TipRanks Sep 9 07:30 | −12.7%next day +3.2% · 5 days +4.4% | ↗ |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $10.00 | Buy | +286.1% | Reiterated | 07.08.26on TipRanks 08:15 | +10.7%next day −8.4% · 5 days −9.5% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $12.00 | Buy | +363.3% | Initiated | 02.06.26on TipRanks 06:31 | −1.8%next day −1.0% · 5 days −1.7% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $14.00 | Buy | +440.5% | Reiterated | 21.11.25on TipRanks Nov 24 08:50 | +0.4%next day −0.1% · 5 days −19.2% | ↗ |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $3.50 → $5.00+42.9% | Buy | +93.1% | Reiterated | 10.11.25on TipRanks 06:30 | −3.7%next day −3.0% · 5 days +3.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering X4 Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $11.00 at a price of $2.90 (+279.3%); now: $11.00 at $2.59 (+324.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 3 | 4 | 5 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.18 (from $-0.21 to $-0.16). Last quarter: $-0.13.
Sales
Next quarter’s sales estimate — $2M (from $2M to $3M). Last quarter: $9M.
Best top-analyst consensus in the sector · Healthcare
About X4 Pharmaceuticals
- CEO: Adam R. Craig
- Employees: 45
- 61 North Beacon Street, Boston, MA, 02134, US
- www.x4pharma.com
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 2 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗